0648 (0648) Fair Value & Analysis

Healthcare · Market cap HK$646M

0 0648 0648 · HK

PriceHK$6.03

Fair ValueHK$1.43

Upside-76.3%

Quality56/100

Evidence: High Range HK$1.02 – HK$1.78

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −72.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1720 – HK$22.40 · fair‑value band HK$1.02 – HK$1.78 · the HK$6.03 price screens above the HK$1.43 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0648 (0648) currently trades at HK$6.03, while our model-based Fair Value estimate is HK$1.43 — implying the stock looks roughly 76.3% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 0648 generated revenue of HK$68.2M at a net margin of 10.2%. Revenue grew 35.7% year over year. It earns a return on equity of 46.6%. The stock trades on a trailing P/E of 25.1. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$68.2M

Revenue growth (YoY) +35.7%

Net margin 10.2%

Return on equity 46.6%

Free cash flow HK$5.4M FY2025

P/E ratio 25.1

More key figures

Operating margin 14.2%

EPS growth (YoY) -99.6%

Net debt HK$72.0K FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0648 reported revenue of HK$68.2M in FY2025 versus HK$1.7M in FY2021, a compound +151.7%/yr. Reported net income was HK$7.0M in FY2025.

Revenue +151.7%/yr

FY21 HK$1.7M

FY22 HK$33.8M

FY23 HK$51.3M

FY24 HK$54.6M

FY25 HK$68.2M

Net income

FY21 −HK$26.3M

FY22 −HK$19.2M

FY23 HK$12.5M

FY24 HK$326M

FY25 HK$7.0M

Is 0648 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$96.00	R$25.67	-73%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0648 (0648) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.43 versus a price of HK$6.03 — about −76% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0648?

Our model-based fair value for 0648 is HK$1.43 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$6.03.

What is the quality score of 0648?

0648 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0648 (0648)?

0648 reported trailing-twelve-month revenue of about HK$68.2M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0648?

The net profit margin of 0648 is about 10.2%, meaning it keeps roughly 10.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.